ArticleFrontiers in pharmacology2026
Ulcerative colitis therapeutic effects and pharmacokinetics of flexible quercetin nanocrystals prepared with geniposide assistance.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to improve the oral bioavailability and therapeutic efficacy of quercetin (QUE) against ulcerative colitis (UC) by formulating flexible quercetin nanocrystals (QUE-NCs) with the assistance of geniposide (Gen). Methods: QUE-NCs were prepared via an antisolvent precipitation method leveraging the interaction between QUE and Gen. Therapeutic efficacy was evaluated in a dextran sulfate sodium (DSS)-induced UC mouse model using disease activity index (DAI), colon histopathology (H&E), and ELISA-based biochemical assays. Biosafety was assessed through serum biochemistry, organ indices, and histopathological examination. An HPLC method was developed and validated for quantifying QUE in rat plasma, followed by a pharmacokinetic study in Wistar rats. Results: QUE-NCs exhibited a flexible rod-like morphology and significantly alleviated UC symptoms, including weight loss, fecal occult blood, and colonic damage. Treatment with QUE-NCs reduced pro-inflammatory cytokines (TNF-α: 173.51 pg·mL Conclusion: Gen-assisted formulation of QUE-NCs improves both the oral absorption and anti-UC efficacy of QUE, offering a promising nanostrategy for flavonoid-based therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.